Former Chief Manufacturing Officer · Mersana Therapeutics, Inc. (MRSN)

Michael Kaufman

A named executive officer of Mersana Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,511,036

Salary $286,180Stock awards $527,250

FY2020: $1,213,821

4th of 7 named executive officers at Mersana Therapeutics by FY2021 total.

7 named officers on file for Mersana Therapeutics, FY2021

Michael Kaufman’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • MRSN’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mersana Therapeutics’s whole pay program stands against its peers

  • Mersana Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MRSN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A).

Free

Get Michael Kaufman’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Kaufman compensation by year

Mersana Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Mersana Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021
Salary$356,000$385,840$398,380$286,180
Bonus$0$0$0$0
Stock awards$0$160,000$164,269$527,250
Option awards$470,511$139,764$459,324$1,656,619
Non-equity incentive$119,250$169,770$184,848$0
Pension and deferred compensation$0$0$0$0
All other$6,000$7,000$7,000$40,988
Total$951,761$862,374$1,213,821$2,511,036

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mersana Therapeutics, Inc. DEF 14A filed April 29, 2022, accession 0001104659-22-052704, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mersana Therapeutics, Inc. filed document, accession 0001104659-22-052704. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

$952K
$862K
$1.2M
$2.5M
FY18
FY19
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Mersana Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Anna ProtopapasFormer President and Chief Executive Officer$8,277,490
Timothy LowingerSenior Vice President, Chief Science and Technology Officer$3,146,148
Brian DeSchuytnerSenior Vice President, Chief Financial Officer$2,754,362
Michael Kaufman · this pageFormer Chief Manufacturing Officer$2,511,036
Alejandra CarvajalSenior Vice President, Chief Legal Officer$2,178,250
Tushar MisraSenior Vice President, Chief Manufacturing Officer$1,455,418
Arvin YangFormer Senior Vice President, Chief Medical Officer$868,960

The full Mersana Therapeutics compensation record

free company brief

This page is one person within Mersana Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mersana Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mersana Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Kaufman's compensation dossier · One-time report. No refunds.